Is Vaxcyte, Inc. (PCVX) a Buy, Sell, or Hold?
NASDAQ : PCVX
Vaxcyte, Inc.
$56.74 USD
$0.53 (0.94%)
- Volume
- 763.08K
- Average Volume
- 1.62M
- Market Capitalization
- $8.19B
- P/E Ratio
- -8.24
- Dividend Yield
- 0.00%
- Price Target
- $89.00
- Year High
- $65.00
- Year Low
- $29.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.49
| Source | Headline |
|---|---|
|
Vaxcyte to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: globenewswire.com - 2026-07-08 16:05:00 |
|
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus globenewswire.com - 2026-06-02 16:05:00 |
|
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript seekingalpha.com - 2026-05-12 19:10:45 |
|
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults globenewswire.com - 2026-05-06 16:05:00 |
|
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation. seekingalpha.com - 2026-05-01 22:59:00 |
